TUESDAY, october 27 | 12:00 PM ET
Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company’s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important
patient-care need for the treatment of molluscum.
Featured Key Opinion Leader
John Browning, MD, FAAD, FAAP, MBA
Clinical Assistant Professor of Pediatrics and Dermatology at Baylor College of Medicine and at the University of Texas Health Science Center at San Antonio; Chief of Dermatology at the Children's Hospital of San Antonio
John Browning, M.D., F.A.A.D, F.A.A.P., MBA is board certified in pediatrics, dermatology, and pediatric dermatology. As the Assistant Professor of Pediatrics and Dermatology and the Chief of Staff of Pediatric Dermatology, Dr. Browning has extensive experience in diagnosing and treating skin conditions in patients of all ages.
Dr. Browning obtained his undergraduate degree from Vanderbilt University Honors Program; he then received his medical degree from the University of Texas Medical School in Galveston and continued his pediatric residency at Baylor College of Medicine in Houston. He is a Fellow of the American Academy of Pediatrics and a Diplomate of the American Board of Pediatrics. Dr. Browning also completed his residency in dermatology at the Baylor College of Medicine; he was Chief Resident in 2006-2007. He is a Diplomate of the American Board of Dermatology and a Pediatric Dermatology Fellow.
Dr. Browning is the Clinical Assistant Professor of Pediatrics and Dermatology at Baylor College of Medicine and at the University of Texas Health Science Center at San Antonio. He also serves as the Chief of Dermatology at the Children’s Hospital of San Antonio.
Members of Management
Paula Brown Stafford
President, Chief Executive Officer, Chairman
Paula Brown Stafford, MPH, is the President and Chief Executive Officer of Novan. Ms. Stafford also serves as Chairman of the Novan Board of Directors. Prior to joining Novan, in March 2017, Ms. Stafford was President of Clinical Development at Quintiles (now IQVIA). In this role, Ms. Stafford was responsible for global clinical development operations. While at Quintiles, Ms. Stafford was a member of the Executive Committee, the Technology Investment Committee, and a Board Observer. In addition to her role at Novan, Ms. Stafford serves on the board of Health Decisions, Inc. and is an adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. Ms. Stafford holds a Bachelor of Science and a Master of Public Health, both from the University of North Carolina at Chapel Hill, with a specialization in Biostatistics.
Carri Geer, Ph.D.
Senior Vice President, Chief Technology Officer
Carri Geer, Ph.D., leads drug substance, drug product, device and analytical development for Novan’s drug candidates. Additionally, Dr. Geer serves as the technical liaison for collaborative partnerships. Dr. Geer has 10 years of experience in pharmaceutical product development, and a background in analytical and bioanalytical chemistry. During her tenure at Novan, Dr. Geer has been responsible for establishing and growing the analytical capabilities of the company. Prior to joining Novan, Dr. Geer was employed at Merck and bridged the interface between R&D and cGMP analytical testing. Dr. Geer received her Ph.D. in Chemistry from the University of North Carolina at Chapel Hill.